Protective effect of ulinastatin against negative inflammatory response and organ dysfunction in acute aortic dissection surgery: The PANDA trial.

• Tác giả: Jun-Quan Chen, Yi-Fei Diao, Guo-Liang Fan, Ao Li, Hai-Yang Li, Hong Liu, Nan Liu, Xiang Liu, Chao Ma, Bu-Qing Ni, Si-Chong Qian, Yong-Feng Shao, Zhi-Wei Tang, Ying Wu, Zhong Wu, Xiu-Fan Xu, Ji-Nong Yang, Hong-Hua Yue, Hong-Jia Zhang, Ying-Yuan Zhang, Sheng Zhao, Kai Zhu
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : Cell reports. Medicine , 2025
• Bộ sưu tập: NCBI
• ID: 678876

Tóm tắt

 Ulinastatin is a protease-inhibiting drug with anti-inflammatory and other pharmacological properties. Little is known regarding its role following acute type A aortic dissection (ATAAD) surgery. We perform a randomized controlled trial to investigate the protective effect of ulinastatin against negative inflammatory response and organ dysfunction in ATAAD surgery (PANDA). The primary outcome of mean daily Sequential Organ Failure Assessment (SOFA) score from baseline to 7 days of surgery is 8.80 (SD, 4.11) in the ulinastatin group and 8.61 (SD, 4.47) in the control group (mean difference between groups was 0.04
  95% confidence interval [CI], -0.24 to 0.33
  p = 0.765). Systemic inflammatory response syndrome (SIRS) within 7 days of surgery is lower in the ulinastatin group than in the control group (p <
  0.001). Additional ulinastatin to standard treatment is likely to reduce SIRS rates instead of preventing organ dysfunction, highlighting the potential importance of the benefits of anti-inflammatory pharmacotherapeutics. The trial is registered on clinicaltrials.org (NCT04711889).